Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128902) titled 'Low-Dose Radiotherapy Sequential with Sacituzumab Tirumotecan and Bemozumab in Immunotherapy-Resistant Metastatic Esophageal Squamous Cell Carcinoma: An Exploratory Study (Radiance-01 Study)' on July 28.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Zhejiang Cancer Hospital
Condition:
Histologically confirmed recurrent or metastatic or unresectable locally advanced ESCC
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-08-01
Target Sample Size: Single arm:33;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj....